FBXW7-AS1 and infection: Most importantly, both murine anti-rat DEspR and humanized anti-rat/human DEspR antibody treatments at acute sICH improved median survival of hsICH-rats, with an empirical resolution of presenting neurological symptoms and without an increased infection risk (14).